| scholarly article | Q13442814 |
| P50 | author | Zenon Huczek | Q56936704 |
| Claudio Moretti | Q57292495 | ||
| Fabrizio D'Ascenzo | Q61163714 | ||
| P2093 | author name string | Yan Yan | |
| José R González-Juanatey | |||
| Xiao Wang | |||
| Stephen B Wilton | |||
| Xian-Tao Song | |||
| Emad Abu-Assi | |||
| Christoph Liebetrau | |||
| Dimitrios Alexopoulos | |||
| Masa-Aki Kawashiri | |||
| Shao-Ping Nie | |||
| Wouter J Kikkert | |||
| Jorge Saucedo | |||
| Sasko Kedev | |||
| Sergio Raposeiras-Roubín | |||
| Toshiharu Fujii | |||
| Tetsuma Kawaji | |||
| Jing-Yao Fan | |||
| Iván Nuñez-Gil | |||
| Albert Ariza-Sole | |||
| Jose P Simao Henriques | |||
| Luis C Correia | |||
| P2860 | cites work | Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin | Q28200091 |
| Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population | Q28548045 | ||
| Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials | Q30421742 | ||
| Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study | Q34009506 | ||
| 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevati | Q34491521 | ||
| Clopidogrel with or without omeprazole in coronary artery disease | Q34660303 | ||
| Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome | Q34956075 | ||
| Prognosis of concomitant users of clopidogrel and proton-pump inhibitors in a high-risk population for upper gastrointestinal bleeding | Q35147463 | ||
| Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials | Q37590925 | ||
| Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis | Q37721156 | ||
| 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi | Q37953885 | ||
| CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis | Q37971875 | ||
| An insight into the interaction between clopidogrel and proton pump inhibitors | Q37980821 | ||
| Ticagrelor: the first novel reversible P2Y(12) inhibitor | Q38069896 | ||
| Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial | Q38477257 | ||
| BleeMACS: rationale and design of the study. | Q40941750 | ||
| Proton pump inhibitor use represents an independent risk factor for myocardial infarction | Q41700008 | ||
| Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel | Q42646492 | ||
| Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study | Q42882409 | ||
| Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis | Q42974062 | ||
| Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel | Q46199177 | ||
| Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 | ||
| 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribu | Q53460540 | ||
| Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction | Q57243377 | ||
| Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation | Q57300220 | ||
| 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary | Q59355889 | ||
| Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction | Q82636199 | ||
| Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators | Q83565343 | ||
| A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers | Q83780327 | ||
| Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies | Q85036168 | ||
| P433 | issue | 3 | |
| P921 | main subject | acute coronary syndrome | Q266018 |
| clopidogrel | Q410237 | ||
| P304 | page(s) | 209-217 | |
| P577 | publication date | 2016-03-01 | |
| P1433 | published in | Journal of Geriatric Cardiology | Q15765238 |
| P1476 | title | Impact of concomitant use of proton pump inhibitors and clopidogrel or ticagrelor on clinical outcomes in patients with acute coronary syndrome | |
| P478 | volume | 13 |
| Q91886489 | Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry | cites work | P2860 |
Search more.